At the same time, non-malignant CD34+ HSCs were not sensitised to ABT-737 by PHA-767491, indicating that Mcl-1 has a differential role in CD34+ cells of AML versus non-malignant HSCs thus offering a therapeutic window to target LSCs. Here, MCL1 is linked to acute myeloid leukemia.